下肢外周动脉疾病血运重建患者中医师指导药物治疗的性别差异
基于Vascular Quality Initiative注册数据,纳入2013至2023年因跛行或慢性肢体威胁性缺血行下肢开放或腔内血运重建的257,129例患者(女性38%)。研究显示术前他汀联合抗血小板使用率稳定在62%,术后从2013年68%升至2023年81%;校正风险后女性术前(OR 0.88,95%CI 0.86-0.89)和术后(OR 0.84,95%CI 0.83-0.86)使用几率均低于男性。
要点
- 下肢PAD血运重建患者术前GDMT使用率长期停滞在62%,术后使用率从68%升至81%。
- 校正风险后女性术前和术后他汀联合抗血小板使用几率均显著低于男性。
- 非西班牙裔黑人、疾病严重度更高(组织丢失 vs 跛行)及急诊就诊者术前GDMT使用几率更低。
核心结论
- 术后GDMT使用比例随时间增加,但术前使用停滞,且性别差异在术前和术后均持续存在。
- 女性下肢PAD血运重建患者接受指南指导药物治疗的几率低于男性。
研究设计与样本
- 回顾性队列研究,基于Vascular Quality Initiative全国血管外科质量改进注册数据库。
- 纳入2013至2023年因跛行或慢性肢体威胁性缺血行下肢开放或腔内血运重建的257,129例患者,女性占38%。
- 暴露为自我报告性别,主要结局为他汀联合抗血小板(阿司匹林或P2Y12抑制剂)使用。
- 采用描述性统计和多层多变量逻辑回归(按中心聚类)分析性别与GDMT使用的时间关联。
主要发现
- 术前他汀联合抗血小板使用率在研究期间稳定在62%,术后从2013年68%升至2023年81%。
- 校正风险后女性术前他汀联合抗血小板使用几率低于男性(OR 0.88,95%CI 0.86-0.89)。
- 校正风险后女性术后他汀联合抗血小板使用几率低于男性(OR 0.84,95%CI 0.83-0.86)。
- 非西班牙裔黑人患者术前使用几率更低(OR 0.96,95%CI 0.94-0.99)。
- 疾病严重度更高(组织丢失 vs 跛行:OR 0.60,95%CI 0.58-0.61)和急诊就诊(OR 0.67,95%CI 0.62-0.73)与术前使用几率更低相关。
关键数值与推荐
- PAD药物治疗GDMT包括他汀和抗血小板药物,已显示可降低主要不良心脏和肢体事件发生率。
- 主要结局定义为他汀联合抗血小板(阿司匹林或P2Y12抑制剂)使用。
- 次要结局包括抗凝药使用及高血压患者中ACEI和/或ARB使用。
临床怎么用
- 应关注下肢PAD血运重建患者术前GDMT的使用不足,尤其女性患者。
- 针对性别差异需开展多学科协作的质量改进措施以缩小治疗差距。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pharmacologic guideline-directed medical therapy (GDMT) for peripheral arterial disease (PAD) includes statin and antiplatelet agents, which has shown to decrease rates of major adverse cardiac and limb events. Despite this, historical use of pharmacologic GDMT has been low. Our objective was to evaluate the association of patient sex with the use of and trends in pre- and postprocedural pharmacologic GDMT among individuals undergoing intervention for infrainguinal PAD. METHODS: We performed a retrospective cohort study of the Vascular Quality Initiative, a national vascular surgery quality improvement registry. The study population included patients with claudication or critical limb-threatening ischemia who underwent index infrainguinal open or endovascular intervention for PAD between 2013 and 2023. The primary exposure was self-reported sex, male or female. The primary outcome was the use of a statin and antiplatelet agent, either aspirin or P2Y12 inhibitor. Secondary outcomes include use of anticoagulants and angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers among individuals with hypertension. We studied the association of sex with pharmacologic GDMT use over time using descriptive statistics and multilevel multivariable logistic regression accounting for clustering by center. RESULTS: Our study cohort included 257,129 patients of whom 38% were female. Although preoperative use of statin and antiplatelet remained steady at 62% over the study period, postoperative use increased from 68% in 2013 to 81% in 2023. Compared with females, males were more likely to be on statin and antiplatelet preoperatively (P < .001) and postoperatively (P < .001) each year. Females had lower odds of statin and antiplatelet use preoperatively [odds ratio (OR), 0.88; 95% confidence interval (CI), 0.86-0.89] and postoperatively (OR, 0.84; 95% CI, 0.83-0.86), even after risk adjustment. Non-Hispanic Black patients (OR, 0.96; 95% CI, 0.94-0.99), increased disease severity (tissue loss vs claudication: OR, 0.60; 95% CI, 0.58-0.61), and emergent presentation (OR, 0.67; 95% CI, 0.62-0.73) were associated with lower odds of preoperative statin and antiplatelet use. CONCLUSIONS: Although the proportion of patients on pharmacologic GDMT postoperatively has increased over time, preoperative use has stagnated despite strong evidence supporting its use. Furthermore, sex-based differences persist at both time points, which may require targeted, multispecialty collaboration in quality improvement efforts to close this gap.
引用
- Ramkumar N, Mosulishvili T, Columbo JA, et al. Use of pharmacologic guideline-directed medical therapy for peripheral artery disease by sex among patients undergoing revascularization. J Vasc Surg. 2026. PMID: 42248488. doi:10.1016/j.jvs.2026.05.049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。